12 Mar 2015

Earlier this year, NHS England announced that they would be removing several drugs, including the prostate cancer treatment cabazitaxel, from the Cancer Drugs Fund (CDF).

That decision comes into effect today, which means that new patients will no longer be able to access this treatment via the CDF. Anyone who is already taking cabazitaxel via the CDF will continue to be able to access this treatment for as long as their doctor recommends it.

We know that cabazitaxel’s manufacturers are challenging the decision to remove this drug from the Cancer Drugs Fund, so we’ll report any developments as we learn of them.

It’s already clear that all this back and forth over the Cancer Drugs Fund is just adding to the already considerable evidence that the system for making expensive cancer drugs available to the people who need them is broken beyond repair. That’s why we’re working together with a number of other cancer charities and representatives from NHS England and other organisations to find a better solution. And together with Breakthrough Breast Cancer, we’re looking to fund some research into what the possible alternatives to the Fund are, and how they might work. We’ll keep you posted on this important project as it develops.

Read this next:

CEO blog: Why we need to overhaul the drug appraisal system

9 Jan 2015

Owen Sharp, our Chief Executive, blogs on the recent headlines regarding the Cancer Drugs Fund and prostate cancer drug Jevtana.

comments powered by Disqus